S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Masimo Stock Forecast, Price & News

-1.64 (-0.57%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
193,490 shs
Average Volume
296,802 shs
Market Capitalization
$15.69 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.

Masimo logo

About Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.


Masimo (NASDAQ:MASI) Hits New 52-Week High at $304.80
November 19, 2021 |  americanbankingnews.com
Masimo Co. (NASDAQ:MASI) CEO Joe E. Kiani Sells 27,599 Shares
November 16, 2021 |  americanbankingnews.com
Masimo Co. (NASDAQ:MASI) CFO Micah W. Young Sells 3,700 Shares
November 16, 2021 |  americanbankingnews.com
Piper Sandler Reiterates Overweight Rating for Masimo (NASDAQ:MASI)
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Electromedical equipment
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.29 per share
Book Value
$26.59 per share


Net Income
$240.30 million
Pretax Margin




Free Float
Market Cap
$15.69 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.92 out of 5 stars

Medical Sector

697th out of 1,391 stocks

Electromedical Equipment Industry

14th out of 30 stocks

Analyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Masimo (NASDAQ:MASI) Frequently Asked Questions

Is Masimo a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Masimo stock.
View analyst ratings for Masimo
or view top-rated stocks.

How has Masimo's stock been impacted by Coronavirus?

Masimo's stock was trading at $182.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MASI stock has increased by 55.6% and is now trading at $284.15.
View which stocks have been most impacted by COVID-19

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Masimo

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Monday, October, 25th. The medical equipment provider reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.03. The medical equipment provider earned $307.40 million during the quarter, compared to analysts' expectations of $295.79 million. Masimo had a trailing twelve-month return on equity of 15.56% and a net margin of 19.23%. Masimo's revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.80 earnings per share.
View Masimo's earnings history

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY 2021 earnings guidance on Tuesday, November, 2nd. The company provided earnings per share guidance of $3.880-$3.880 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.790. The company issued revenue guidance of $1.23 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

What price target have analysts set for MASI?

3 equities research analysts have issued 1-year target prices for Masimo's shares. Their forecasts range from $285.00 to $330.00. On average, they expect Masimo's stock price to reach $308.33 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Masimo
or view top-rated stocks among Wall Street analysts.

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Joe E. Kiani, Chairman & Chief Executive Officer
  • Bilal Muhsin, Chief Operating Officer
  • Micah Young, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Yongsam Lee, Chief Information Officer & Executive VP
  • Anand Sampath, Executive VP-Operations & Clinical Research

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo CEO Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among Masimo's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (16.11%), Ownership Capital B.V. (3.64%), Invesco Ltd. (2.10%), Massachusetts Financial Services Co. MA (1.53%), RTW Investments LP (1.51%) and Credit Suisse AG (1.42%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Eagle Asset Management Inc., Credit Suisse AG, Citigroup Inc., Schroder Investment Management Group, Ensemble Capital Management LLC, UBS Group AG, and Goldman Sachs Group Inc.. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Craig B Reynolds, Joe E Kiani, and Micah W Young.
View insider buying and selling activity for Masimo
or view top insider-selling stocks.

Which major investors are buying Masimo stock?

MASI stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sumitomo Mitsui Trust Holdings Inc., Martin Currie Ltd., Mitsubishi UFJ Trust & Banking Corp, Ownership Capital B.V., Morgan Stanley, Eversept Partners LP, and BNP Paribas Asset Management Holding S.A..
View insider buying and selling activity for Masimo
or or view top insider-buying stocks.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $284.15.

How much money does Masimo make?

Masimo has a market capitalization of $15.69 billion and generates $1.14 billion in revenue each year. The medical equipment provider earns $240.30 million in net income (profit) each year or $4.01 on an earnings per share basis.

How many employees does Masimo have?

Masimo employs 2,000 workers across the globe.

When was Masimo founded?

Masimo was founded in 1989.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

Where are Masimo's headquarters?

Masimo is headquartered at 52 DISCOVERY, IRVINE CA, 92618.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at (949) 297-7000, via email at [email protected], or via fax at 949-297-7001.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.